Rhythm Pharmaceuticals, Inc.
Key Metrics
- Previous Close
- $119.04
- 52-Week Range
- $74.50 – $122.20
- Market Cap
- $8.10B
- P/E (TTM)
- —
- EPS (TTM)
- -2.85
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 92.04
- PEG Ratio
- —
- Return on Equity
- -77.96%
- Return on Assets
- -24.64%
- Gross Margin
- 88.23%
- Operating Margin
- -66.70%
- Profit Margin
- -69.03%
- Current Ratio
- 2.78
- Debt/Equity
- 0.53
- Total Debt
- $106.18M
- Free Cash Flow
- $-17.76M
- Revenue Growth
- 79.60%
- Earnings Growth
- —
- Enterprise Value
- $8.00B
Market Snapshot
About
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity. The company markets setmelanotide, an FDA-approved melanocortin-4 receptor agonist for treating rare diseases caused by impaired MC4R pathway signaling. Rhythm is advancing a pipeline of peptide therapeutics targeting genetic obesity and related metabolic disorders.